Stimcell Energetics Inc. Files 10-Q for Nov 30, 2024

TL;DR

Stimcell Energetics (STME) filed their 10-Q for Nov 30, 2024. Check financials.

AI Summary

Stimcell Energetics Inc. filed a 10-Q for the period ending November 30, 2024. The company, formerly known as Cell MedX Corp., is based in Vancouver, NV, and operates in the Surgical & Medical Instruments & Apparatus industry. The filing covers financial information for the quarter and year-to-date periods.

Why It Matters

This filing provides investors with an update on Stimcell Energetics Inc.'s financial performance and position for the period ending November 30, 2024, crucial for assessing the company's health and future prospects.

Risk Assessment

Risk Level: medium — As a 10-Q filing, it contains detailed financial information which can reveal significant operational and financial risks.

Key Players & Entities

• Stimcell Energetics Inc. (company) — Filer of the 10-Q
• Cell MedX Corp. (company) — Former name of Stimcell Energetics Inc.
• November 30, 2024 (date) — End of the reporting period
• 20250114 (date) — Filing date

FAQ

Key Financial Figures

• $3,165 — areholder, agreed to forgive a total of $3,165 the Company owed for royalties. The for
• $30,000 — re unsecured and payable on demand. The $30,000 loan was payable on April 24, 2023, and
• $100,000 — . The remaining notes payable, totaling $100,000, are payable on demand. During the six-
• $5,851 — November 30, 2024, the Company recorded $5,851 in interest on the principal (November
• $5,087 — t on the principal (November 30, 2023 - $5,087). Notes payable with a significant sha
• $0 — hares of common stock with par value of $0.001, of which 297,236,373 shares were o
• $42,562 — ating expenses increased by 207.1% from $42,562 incurred during the three months ended
• $130,698 — hree months ended November 30, 2023, to $130,698 incurred during the three months ended
• $46,133 — he largest change was associated with a $46,133 increase in foreign exchange loss due t
• $4,641 — to the US dollar, which increased from $4,641 the Company recognized during the three
• $50,774 — hree months ended November 30, 2023, to $50,774 recognized for the period ended Novembe
• $22,500 — cond largest change was associated with $22,500 the Company incurred in management fees
• $34,743 — 2023. In addition, the Company incurred $34,743 in consulting fees, which increased by
• $5,273 — in consulting fees, which increased by $5,273 as compared to $29,470 the Company incu
• $29,470 — hich increased by $5,273 as compared to $29,470 the Company incurred during the three m

Filing Documents

• stme-20241130.htm (10-Q) — 475KB
• stme_ex1073.htm (EX-10.73) — 11KB
• stme_ex311.htm (EX-31.1) — 6KB
• stme_ex312.htm (EX-31.2) — 6KB
• stme_ex321.htm (EX-32.1) — 3KB
• stme_ex322.htm (EX-32.2) — 4KB
• 0001393905-25-000019.txt ( ) — 1913KB
• stme-20241130_cal.xml (EX-101.CAL) — 19KB
• stme-20241130_def.xml (EX-101.DEF) — 40KB
• stme-20241130_lab.xml (EX-101.LAB) — 103KB
• stme-20241130_pre.xml (EX-101.PRE) — 89KB
• stme-20241130.xsd (EX-101.SCH) — 19KB
• stme-20241130_htm.xml (XML) — 209KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 1

Financial Statements

Item 1. Financial Statements 1

Management ' s Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 2

Quantitative and Qualitative Disclosure about Market Risk

Item 3. Quantitative and Qualitative Disclosure about Market Risk 5

Controls and Procedures

Item 4. Controls and Procedures 5

- OTHER INFORMATION

PART II - OTHER INFORMATION 7

Legal Proceedings

Item 1. Legal Proceedings 7

Risk Factors

Item 1A. Risk Factors 7

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 12

Defaults upon Senior Securities

Item 3. Defaults upon Senior Securities 12

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 12

Other Information

Item 5. Other Information 12

Exhibits

Item 6. Exhibits 13

SIGNATURES

SIGNATURES 16 iii

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements The accompanying unaudited condensed consolidated financial statements of Stimcell Energetics Inc. (formerly, Cell MedX Corp.) as at November 30, 2024, have been prepared by the Company's management in conformity with accounting principles generally accepted in the United States of America and in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X and, therefore, do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' deficit in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Operating results for the three- and six-month periods ended November 30, 2024, are not necessarily indicative of the results that can be expected for the year ending May 31, 2025. As used in this Quarterly Report, the terms "we," "us," "our," "Stimcell," "Stimcell Energetics," and the "Company" mean Stimcell Energetics Inc. (fka "Cell MedX Corp.") and its subsidiary, Cell MedX (Canada) Corp., unless otherwise indicated. All dollar amounts in this Quarterly Report are expressed in U.S. dollars. 1 STIMCELL ENERGETICS INC. (Formerly, CELL MEDX CORP.) CONDENSED CONSOLIDATED BALANCE SHEETS (EXPRESSED IN US DOLLARS) (UNAUDITED) November 30, 2024 May 31, 2024 ASSETS Current assets Cash $ 33,821 $ 43,415 Other current assets 4,525 2,707 Total assets $ 38,346 $ 46,122 LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities Accounts payable $ 316,282 $ 288,891 Accrued liabilities 12,340 28,058 Due to related parties 325,945 231,138 Notes and advances due to related parties 366,484 324,490 Total liabilities 1,021,051 872,577 STOCKHOLDERS' DEFICIT Common st

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion of the Company's financial condition and results of operations should be read in conjunction with the Company's unaudited condensed consolidated financial statements, the notes to those financial statements and other financial information appearing elsewhere in this document. In addition to historical information, the following discussion and other parts of this document contain forward-looking statements that reflect plans, estimates, intentions, expectations and beliefs. Actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those set forth in the "Risk Factors" in Part II, Item 1A of this Quarterly Report. The discussion provided in this Quarterly Report should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended May 31, 2024, filed with the United States Securities and Exchange Commission (the "SEC") on August 29, 2024. Overview The Company was incorporated under the laws of the State of Nevada on March 19, 2010. On April 26, 2016, the Company formed a wholly owned subsidiary, Cell MedX (Canada) Corp., ("Cell MedX Canada", or the "Subsidiary") under the laws of the Province of British Columbia. Effective November 1, 2024, the Company completed a 1-for-15 reverse split (the "Reverse Split") of its common stock. As a result of the Reverse Split, the Company's authorized capital was decreased from 7,500,000,000 shares of common stock with par value of $0.001, of which 297,236,373 shares were outstanding immediately prior to the Reverse Split, to 500,000,000 shares of common stock with par value of $0.001, of which 19,816,272 were outstanding. All share and per-share amounts in this Quarterly Report on Form 10-Q have been retrospectively adjusted. Concurrent with the Reverse Sp

View Full Filing

View this 10-Q filing on SEC EDGAR